GO:0035269 protein O-linked glycosylation via mannose: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035269 (protein O-linked glycosylation via mannose) describes the biosynthetic process that begins with covalent attachment of a mannose residue via an alpha-glycosidic bond to the oxygen atom of a serine or threonine side chain in a protein, which can then be elongated with additional sugars.
• The best-characterized substrate of this pathway in humans is alpha-dystroglycan (DAG1), whose O-mannosylation is required for sarcolemma resilience and skeletal muscle health.
• Defects in O-mannosylation underlie dystroglycanopathies, a group of congenital muscular dystrophies with brain and eye abnormalities.
• O-mannosylation is functionally distinct from N-glycosylation and from other O-glycosylation types; it is initiated in the endoplasmic reticulum and extended in the Golgi apparatus.
• CRISPR screens combined with lectin microarrays have been used to identify regulators of high-mannose glycan structures, providing a scalable approach to dissect glycosylation pathways.
• Glycosylation changes, including mannose-containing glycans, are associated with cancer progression, epithelial-to-mesenchymal transition, and immune modulation [1,7,8].
Description
Protein O-linked glycosylation via mannose (GO:0035269) is a biological process in which a mannose sugar is covalently attached through an alpha-glycosidic bond to the oxygen atom of a serine or threonine residue on a target protein, followed by optional elongation with additional sugar units. This modification is a specialized form of O-glycosylation that is distinct from the more common O-GalNAc and O-GlcNAc modifications, and it is essential for the function of a small but critical set of proteins, most notably alpha-dystroglycan. The pathway is initiated in the endoplasmic reticulum and completed in the Golgi apparatus, where a series of glycosyltransferases sequentially add mannose and other sugars to build a mature O-mannosyl glycan. Researchers study GO:0035269 because defects in this pathway cause severe human diseases, including congenital muscular dystrophies known as dystroglycanopathies, which present with muscle weakness, brain malformations, and eye abnormalities. In addition, mannose-containing glycans influence cancer immunotherapy and radiotherapy responses, as shown by studies where D-mannose treatment promoted degradation of PD-L1 in triple-negative breast cancer. High-mannose N-glycan regulators have also been identified through CRISPR screens and lectin microarrays, highlighting the broader importance of mannose metabolism in glycobiology. Understanding the molecular players and regulatory mechanisms of protein O-linked glycosylation via mannose is therefore relevant to muscle biology, neurodevelopment, cancer immunology, and biotherapeutic production [3,4]. This article summarizes the current knowledge of the pathway, its key genes, disease associations, and experimental methods used to study it.
protein O-linked glycosylation via mannose At A Glance
| GO ID | GO:0035269 |
|---|---|
| GO term | protein O-linked glycosylation via mannose |
| Ontology | biological_process |
| Synonym | protein amino acid O-linked mannosylation; protein O-linked mannosylation |
| Major function | Covalent attachment of mannose to serine/threonine residues of proteins, followed by glycan elongation, critical for protein stability and function |
| Substrate | Proteins with serine or threonine residues, notably alpha-dystroglycan |
| Cellular location | Endoplasmic reticulum and Golgi apparatus |
| Key enzyme | Protein O-mannosyltransferases (POMT1/POMT2) |
| Related diseases | Dystroglycanopathies, congenital muscular dystrophies |
What Is GO:0035269?
GO:0035269, protein O-linked glycosylation via mannose, is defined as a glycoprotein biosynthetic process that starts with the covalent linkage of a mannose via an alpha-glycosidic bond to the oxygen atom of a serine or threonine side chain in a protein, which can be further elongated with the sequential addition of sugar units resulting in the formation of a protein O-linked glycan. In simpler terms, it is the process of attaching a mannose sugar to a protein and then potentially building a longer sugar chain on that mannose.
Why Is protein O-linked glycosylation via mannose Important in Cell Biology?
Protein O-linked glycosylation via mannose is critically important because it is required for the proper function of alpha-dystroglycan, a protein that links the extracellular matrix to the cytoskeleton in muscle and brain. Disruption of this pathway causes dystroglycanopathies, a group of severe congenital muscular dystrophies often accompanied by brain and eye abnormalities. Beyond muscle disease, mannose-containing glycans modulate cancer progression and immune responses, as D-mannose can promote PD-L1 degradation and enhance immunotherapy in triple-negative breast cancer. Additionally, glycosylation pathways are central to the production of therapeutic antibodies, where modulation of antibody glycosylation in CHO cells is a key bioprocess parameter. Thus, understanding GO:0035269 has broad implications for human genetics, cancer biology, and biopharmaceutical development.
• Required for alpha-dystroglycan function and sarcolemma resilience in skeletal muscle.
• Defects cause dystroglycanopathies, including Walker-Warburg syndrome and muscle-eye-brain disease.
• Mannose-containing glycans influence cancer immunotherapy and radiotherapy responses.
• High-mannose N-glycan regulators can be identified by CRISPR screens and lectin microarrays.
• Glycosylation changes are associated with epithelial-to-mesenchymal transition in cancer.
• Antibody glycosylation, including mannose content, is critical for therapeutic efficacy and is modulated in CHO cells.
• N-glycoproteomics and proteomics reveal glycosylation changes in diseases such as nasopharyngeal carcinoma.
• Dolichol metabolism defects affect glycosylation pathways, including O-mannosylation.
• ER quality control via UGGT1 reglucosylation competes with degradation of misfolded glycoproteins, impacting glycosylation efficiency.
• O-mannosylation is essential for normal brain and eye development.
What Happens During protein O-linked glycosylation via mannose?
Initiation in the endoplasmic reticulum
In simple terms: The first step happens in the ER, where a mannose sugar is attached to a protein.
The process begins in the endoplasmic reticulum (ER) with the transfer of a mannose residue from dolichol-phosphate-mannose to a serine or threonine residue on the target protein, catalyzed by protein O-mannosyltransferases (POMT1 and POMT2). This initial step is essential for the subsequent elongation and function of the glycoprotein, as demonstrated by the requirement of O-mannosylation for dystroglycan function.
Elongation in the Golgi apparatus
In simple terms: After the first mannose is added, additional sugars are attached in the Golgi to build a longer chain.
Following initiation, the O-mannosyl glycan is further elongated in the Golgi apparatus by a series of glycosyltransferases that sequentially add sugars such as N-acetylglucosamine, galactose, and sialic acid. This elongation generates a mature O-mannosyl glycan that is often referred to as a matriglycan, which is crucial for the ligand-binding functions of alpha-dystroglycan.
Substrate recognition and protein targets
In simple terms: Only certain proteins with specific features get this mannose modification.
O-mannosylation is directed to specific proteins, with alpha-dystroglycan being the most studied substrate in humans. The modification occurs on serine or threonine residues within particular sequence contexts, and the enzymes POMT1/POMT2 recognize these motifs. Other proteins may also be O-mannosylated, but their identities and functions are less well characterized.
Functional consequences of O-mannosylation
In simple terms: The mannose chain helps the protein interact with other molecules and maintain tissue structure.
The O-mannosyl glycan on alpha-dystroglycan mediates binding to extracellular matrix proteins such as laminin, providing a link between the cytoskeleton and the extracellular matrix. This interaction is critical for sarcolemma resilience and skeletal muscle health, as mice lacking O-mannosylation in muscle show severe dystrophic phenotypes. In cancer, mannose-containing glycans can influence immune checkpoint regulation, as D-mannose promotes PD-L1 degradation.
Regulation and quality control
In simple terms: Cells monitor glycosylation and can degrade proteins if something goes wrong.
The ER quality control machinery, including UGGT1-mediated reglucosylation, competes with ER-associated degradation of unstable and misfolded glycoproteins, thereby influencing the efficiency of glycosylation pathways. Defects in dolichol metabolism, which supplies the mannose donor dolichol-phosphate-mannose, can impair O-mannosylation and cause disease. Thus, the pathway is tightly regulated at multiple levels.
Key Genes Involved in GO:0035269 protein O-linked glycosylation via mannose
The following genes encode enzymes, substrates, and regulators directly involved in protein O-linked glycosylation via mannose (GO:0035269) or in related mannose-glycan biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| POMT1 | Protein O-mannosyltransferase 1; initiates O-mannosylation in ER | Mutations cause dystroglycanopathies; target for KO and point mutation studies |
| POMT2 | Protein O-mannosyltransferase 2; forms complex with POMT1 | Required for O-mannosylation; mutations cause muscular dystrophy |
| DAG1 | Dystroglycan; major substrate of O-mannosylation | Central to sarcolemma resilience; KO models show muscle defects |
| POMGNT1 | Protein O-linked mannose beta-1,2-N-acetylglucosaminyltransferase 1; elongates O-mannosyl glycan | Mutations cause muscle-eye-brain disease; key for glycan elongation |
| POMGNT2 | Protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase 2; elongates glycan | Involved in matriglycan synthesis; disease relevance |
| FKTN | Fukutin; glycosyltransferase involved in O-mannosyl glycan synthesis | Mutations cause Fukuyama congenital muscular dystrophy |
| FKRP | Fukutin-related protein; glycosyltransferase for O-mannosyl glycan | Mutations cause limb-girdle muscular dystrophy |
| LARGE1 | Glycosyltransferase that extends matriglycan on alpha-dystroglycan | Overexpression can rescue dystroglycanopathy models |
| B3GALNT2 | Beta-1,3-N-acetylgalactosaminyltransferase 2; adds GalNAc to O-mannosyl glycan | Mutations linked to dystroglycanopathies |
| B4GAT1 | Beta-1,4-glucuronyltransferase 1; involved in glycan elongation | Required for matriglycan synthesis |
| ISPD | Isoprenoid synthase domain containing; involved in dolichol-phosphate-mannose synthesis | Mutations cause dystroglycanopathy |
| DPM1 | Dolichol-phosphate mannosyltransferase subunit 1; synthesizes mannose donor | Defects affect O-mannosylation; related to dolichol metabolism disorders |
| DPM2 | Dolichol-phosphate mannosyltransferase subunit 2 | Part of mannose donor synthesis; relevant to glycosylation |
| DPM3 | Dolichol-phosphate mannosyltransferase subunit 3 | Mutations cause muscular dystrophy; affects O-mannosylation |
| UGGT1 | UDP-glucose:glycoprotein glucosyltransferase 1; ER quality control | Regulates glycoprotein folding and degradation, impacting glycosylation |
| MGAT5 | Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase; N-glycan branching | Identified in CRISPR screens for high-mannose N-glycan regulators |
| DDOST | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase; N-glycosylation | Potential regulator of high-mannose glycans |
How Is protein O-linked glycosylation via mannose Regulated?
The process of protein O-linked glycosylation via mannose is regulated at multiple levels. The availability of the mannose donor dolichol-phosphate-mannose, synthesized by the DPM1/DPM2/DPM3 complex, controls the rate of initiation. ER quality control mechanisms, such as UGGT1-mediated reglucosylation, compete with ER-associated degradation and influence the folding and stability of glycoproteins, thereby indirectly affecting glycosylation efficiency. In cancer, D-mannose availability can modulate PD-L1 degradation, linking mannose metabolism to immune regulation. Additionally, CRISPR screens have identified genes such as MGAT5 and DDOST that regulate high-mannose N-glycan levels, suggesting broader regulatory networks.
protein O-linked glycosylation via mannose and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| POMT1 | Walker-Warburg syndrome, dystroglycanopathy | KO and point-mutation cell models; muscle differentiation assays |
| POMT2 | Congenital muscular dystrophy with brain and eye anomalies | Knock-in of patient mutations in iPSC-derived myocytes |
| DAG1 | Muscular dystrophy, sarcolemma fragility | Muscle-specific KO mice; overexpression of glycosylated DAG1 |
| FKRP | Limb-girdle muscular dystrophy 2I | Knock-in mouse models; AAV-mediated gene replacement |
| DPM3 | Muscular dystrophy with dolichol metabolism defect | KO cell lines; complementation with wild-type DPM3 |
Dystroglycanopathies and congenital muscular dystrophies
Mutations in genes required for O-mannosylation of alpha-dystroglycan cause a spectrum of congenital muscular dystrophies known as dystroglycanopathies, which often include brain and eye abnormalities. These disorders highlight the essential role of GO:0035269 in muscle and neuronal development. Mouse models with muscle-specific loss of O-mannosylation show severe dystrophic phenotypes, confirming the pathway's requirement for sarcolemma resilience.
Cancer immunotherapy and radiotherapy
D-mannose, a sugar involved in mannose metabolism, facilitates immunotherapy and radiotherapy of triple-negative breast cancer by promoting degradation of PD-L1. This suggests that mannose-related glycosylation pathways can influence immune checkpoint regulation and treatment responses. Additionally, high-mannose N-glycan regulators identified through CRISPR screens may affect tumor cell surface glycosylation and immune recognition.
Glycosylation in cancer progression and EMT
Glycosylation changes, including mannose-containing structures, are associated with epithelial-to-mesenchymal transition (EMT) and cancer progression. Proteomics and N-glycoproteomics studies in nasopharyngeal carcinoma have revealed altered glycosylation patterns that may contribute to pathogenesis. These findings link mannose glycosylation to tumor biology and metastasis.
Dolichol metabolism disorders
Genetic defects in dolichol metabolism, which affect the synthesis of dolichol-phosphate-mannose, can impair O-mannosylation and cause a range of clinical phenotypes including muscular dystrophy and neurological abnormalities. These disorders underscore the importance of the mannose donor pathway for GO:0035269.
From protein O-linked glycosylation via mannose-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of POMT1 abolish O-mannosylation of dystroglycan? | POMT1 knockout cell lines (e.g., HEK293, C2C12) |
| Can a patient point mutation in POMT2 be rescued by wild-type allele? | Point-mutation knock-in via CRISPR in iPSCs |
| Does overexpression of LARGE1 enhance matriglycan and improve muscle function? | LARGE1 overexpression in dystroglycanopathy mouse models |
| What genes regulate high-mannose glycan levels? | Genome-wide CRISPR knockout screens coupled with lectin microarrays |
| How does D-mannose affect PD-L1 glycosylation and degradation? | D-mannose treatment in triple-negative breast cancer cell lines; PD-L1 KO models |
| What is the role of UGGT1 in glycosylation quality control? | UGGT1 knockout or knockdown cells; ERAD assays |
How to Study the protein O-linked glycosylation via mannose Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lectin microarray | High-mannose glycan levels on cell surface | CRISPR screen readout for glycosylation regulators |
| N-glycoproteomics | Site-specific glycosylation of proteins | Disease biomarker discovery in cancer |
| Mass spectrometry | Glycan composition and structure | Characterization of O-mannosyl glycans on dystroglycan |
| Western blot with glycan-specific antibodies | Presence of O-mannosyl epitopes | Validation of O-mannosylation in KO cells |
| CRISPR knockout screening | Gene essentiality for glycosylation | Identification of novel regulators |
| Computational modeling | Glycosylation pathway dynamics | Antibody glycoform prediction in CHO cells |
| Immunofluorescence | Localization of glycosylated proteins | Muscle sarcolemma integrity assessment |
| ERAD assays | Glycoprotein degradation rates | Quality control studies involving UGGT1 |
CRISPR screens and lectin microarrays
CRISPR screens combined with lectin microarrays enable systematic identification of genes that regulate high-mannose N-glycan structures. This approach can be adapted to study O-mannosylation by using lectins specific for O-mannosyl glycans. The method allows unbiased discovery of glycosylation regulators and has been validated in mammalian cells.
Glycoproteomics and mass spectrometry
Proteomics combined with N-glycoproteomics can reveal global changes in glycosylation patterns in diseases such as nasopharyngeal carcinoma. Mass spectrometry-based methods can detect and quantify O-mannosyl glycans on specific proteins, providing insights into pathway activity. These techniques are essential for mapping the glycan structures generated by GO:0035269.
Antibody glycosylation analysis in CHO cells
Modulation of antibody glycosylation in Chinese hamster ovary (CHO) cells can be studied using experimental and computational analyses to provide mechanistic insights. This is relevant for biotherapeutic production, where mannose content affects antibody function. Methods include glycan profiling, LC-MS, and modeling of glycosylation pathways.
Genetic and biochemical assays for O-mannosylation
Biochemical assays using radioactive mannose or specific antibodies against O-mannosyl glycans can directly measure O-mannosylation activity. Genetic approaches such as knockout and knock-in in cell lines and animal models are used to dissect the pathway's role in muscle and brain. These methods are critical for validating gene function in GO:0035269.
How CRISPR Can Be Used to Study GO:0035269 protein O-linked glycosylation via mannose
Knockout
CRISPR knockout of genes such as POMT1, POMT2, or DAG1 can abolish O-mannosylation and reveal its functional consequences in cell models. For example, POMT1 knockout cells show loss of dystroglycan glycosylation and impaired laminin binding. These models are valuable for studying dystroglycanopathies and for validating drug targets.
Point Mutation
Introducing patient-specific point mutations (e.g., in POMT2 or FKRP) via CRISPR base editing or homology-directed repair allows researchers to model dystroglycanopathies with precise genetic lesions. Such models can be used to test allele-specific therapies or to study genotype-phenotype correlations.
Knock-in
Knock-in of tagged versions of DAG1 or POMT1 (e.g., HA or GFP tags) enables visualization and purification of O-mannosylated proteins. This approach facilitates interaction studies and live-cell imaging of glycosylation dynamics. Knock-in of wild-type alleles can also rescue patient mutations in iPSC-derived models.
Overexpression
Overexpression of LARGE1, a glycosyltransferase that extends matriglycan, can enhance O-mannosylation and improve muscle function in dystroglycanopathy models. Overexpression of D-mannose metabolism genes may also modulate PD-L1 degradation and immunotherapy responses. These gain-of-function models are useful for therapeutic development.
How EDITGENE Supports protein O-linked glycosylation via mannose Research
Researchers studying protein O-linked glycosylation via mannose-related genes often need to determine whether a candidate gene is causally involved in the pathway, how specific mutations affect enzyme activity, and whether restoring gene function can rescue disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and scale.
Contact EDITGENE today to design your custom CRISPR model for protein O-linked glycosylation via mannose research.
Frequently Asked Questions About protein O-linked glycosylation via mannose
What is protein O-linked glycosylation via mannose?
It is a biological process (GO:0035269) where a mannose sugar is attached to a serine or threonine residue on a protein, which can then be elongated with additional sugars.
What genes are involved in protein O-linked glycosylation via mannose?
Key genes include POMT1, POMT2, DAG1, POMGNT1, POMGNT2, FKTN, FKRP, LARGE1, B3GALNT2, B4GAT1, ISPD, and DPM1-3 [4,5].
Which diseases are linked to defects in O-mannosylation?
Mutations in O-mannosylation genes cause dystroglycanopathies, a group of congenital muscular dystrophies often with brain and eye abnormalities.
How is protein O-linked glycosylation via mannose studied?
Methods include CRISPR knockout screens, lectin microarrays, glycoproteomics, mass spectrometry, and biochemical assays [2,4,7].
What is the role of DAG1 in O-mannosylation?
DAG1 encodes dystroglycan, the major substrate of O-mannosylation; its glycosylation is essential for muscle sarcolemma integrity.
Can CRISPR be used to model dystroglycanopathies?
Yes, CRISPR knockout and point-mutation knock-in in cell and animal models are widely used to study dystroglycanopathy genes.
What is the difference between O-mannosylation and N-glycosylation?
O-mannosylation attaches mannose to serine/threonine, while N-glycosylation attaches glycans to asparagine; they use different enzymes and occur in different cellular compartments.
How does D-mannose affect cancer immunotherapy?
D-mannose can promote PD-L1 degradation and enhance immunotherapy and radiotherapy in triple-negative breast cancer.
What are high-mannose N-glycan regulators?
Genes that control the abundance of high-mannose N-glycans, identified by CRISPR screens and lectin microarrays.
Why is antibody glycosylation important in CHO cells?
Modulation of antibody glycosylation, including mannose content, affects therapeutic efficacy and is a key bioprocess parameter.
Conclusion
Protein O-linked glycosylation via mannose (GO:0035269) is a specialized glycosylation pathway essential for the function of alpha-dystroglycan and for muscle and brain development. Defects in this pathway cause severe congenital muscular dystrophies, and emerging evidence links mannose glycobiology to cancer immunotherapy and biotherapeutic production [1,3,4]. Understanding the genes, mechanisms, and regulatory networks of this pathway is therefore of broad biomedical importance. EDITGENE provides comprehensive CRISPR services, including knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics, to support research on GO:0035269 and related glycosylation pathways. By leveraging these tools, researchers can accelerate discoveries in muscular dystrophy, cancer, and glycobiology.
References
- 1. Zhang R et al.. 2022. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.. Proc Natl Acad Sci U S A 119(8) PMID: 35181605
- 2. Tsui CK et al.. 2024. CRISPR screens and lectin microarrays identify high mannose N-glycan regulators.. Nat Commun 15(1):9970 PMID: 39557836
- 3. Pranomphon R et al.. 2025. Modulation of Antibody Glycosylation in Chinese Hamster Ovary Cells: Experimental and Computational Analyses Provide Mechanistic Insights.. Biotechnol J 20(10):e70143 PMID: 41139990
- 4. Hord JM et al.. 2025. Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan.. Skelet Muscle 15(1):1 PMID: 39789642
- 5. Buczkowska A et al.. 2015. Genetic defects in dolichol metabolism.. J Inherit Metab Dis 38(1):157-69 PMID: 25270028
- 6. Ninagawa S et al.. 2024. UGGT1-mediated reglucosylation of N-glycan competes with ER-associated degradation of unstable and misfolded glycoproteins.. Elife 12 PMID: 39654396
- 7. Chen X et al.. 2025. Proteomics Combined with N-Glycoproteomics to Explore the Pathogenesis of Nasopharyngeal Carcinoma.. J Proteome Res 24(12):6272-6284 PMID: 41269767
- 8. Pucci M et al.. 2021. Glycobiology of the Epithelial to Mesenchymal Transition.. Biomedicines 9(7) PMID: 34356834
